Tricida to Report First Quarter Financial Results and Host Conference Call and Webcast on Tuesday, May 10, 2022

Rhea-AI Summary

Tricida, Inc. (Nasdaq: TCDA) will report its first quarter 2022 financial results on May 10, 2022, after market close. A conference call and webcast to discuss the results and business progress will be held at 4:30 pm Eastern Time. The company is focused on developing veverimer, aimed at slowing CKD progression in patients with metabolic acidosis. Currently, no FDA-approved therapies exist for this condition, affecting approximately 4.3 million patients in the U.S. Interested parties can access the call via their investor relations webpage.

Positive

• Tricida is developing veverimer, addressing a significant unmet medical need in CKD.
• The ongoing VALOR-CKD trial aims to prove veverimer's efficacy in slowing CKD progression.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Tricida, Inc. (Nasdaq: TCDA) today announced that it will report its first quarter 2022 financial results after the close of market on Tuesday, May 10, 2022. Tricida will host a conference call and webcast at 4:30 pm Eastern Time to discuss its first quarter financial results and business progress. The call or webcast may be accessed as follows:

Tricida Conference Call Information

Tricida will host its First Quarter Financial Results and Business Update Conference Call and webcast on Tuesday, May 10, 2022, at 4:30 pm Eastern Time. The call or webcast may be accessed as follows:

Tricida Conference Call
Tuesday, May 10, 2022
4:30 pm Eastern Time
Webcast:	IR.Tricida.com
Dial-In:	(877) 377-5478
International:	(629) 228-0740
Conference ID:	1650033

A replay of the webcast will be available on Tricida’s website approximately two hours following the completion of the call and will be available for up to 90 days following the presentation.

About Tricida

Tricida, Inc. is a pharmaceutical company focused on the development and commercialization of its investigational drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to slow CKD progression in patients with metabolic acidosis and CKD. Tricida is currently conducting a renal outcomes clinical trial, VALOR-CKD, to determine if veverimer slows CKD progression in patients with metabolic acidosis and CKD. Metabolic acidosis is a condition commonly caused by CKD that is believed to accelerate the progression of kidney deterioration. It is estimated to pose a health risk to approximately 4.3 million patients with CKD in the United States. There are currently no therapies approved by the FDA to slow progression of kidney disease by correcting chronic metabolic acidosis in patients with CKD.

For more information about Tricida, please visit www.Tricida.com.

Contact:
Jackie Cossmon
Tricida, Inc.
Senior Vice President of Investor Relations and Communications
IR@Tricida.com

Source: Tricida, Inc.

FAQ

When will Tricida report its financial results for Q1 2022?

Tricida will report its first quarter 2022 financial results on May 10, 2022, after market close.

What is the purpose of Tricida's conference call on May 10, 2022?

The conference call will discuss Tricida's first quarter financial results and business progress.

How can investors access Tricida's conference call?

Investors can access the call via Tricida's investor relations website or by dialing (877) 377-5478.

What is veverimer and its significance for CKD patients?

Veverimer is an investigational drug designed to slow CKD progression in patients with metabolic acidosis, a critical health issue.

How many patients in the U.S. are affected by metabolic acidosis related to CKD?

Approximately 4.3 million patients in the U.S. are estimated to be affected by metabolic acidosis related to CKD.